Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Liver resection and transplantation for intrahepatic cholangiocarcinoma.

Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G.

J Hepatol. 2020 Feb;72(2):364-377. doi: 10.1016/j.jhep.2019.11.020. Review.

PMID:
31954498
2.

Risk-adjusted benchmarks in laparoscopic liver surgery in a national cohort.

Russolillo N, Aldrighetti L, Cillo U, Guglielmi A, Ettorre GM, Giuliante F, Mazzaferro V, Dalla Valle R, De Carlis L, Jovine E, Ferrero A; I Go MILS Group.

Br J Surg. 2020 Jan 10. doi: 10.1002/bjs.11404. [Epub ahead of print]

PMID:
31925777
3.

Gastroblastoma in Adulthood-A Rarity among Rare Cancers-A Case Report and Review of the Literature.

Centonze G, Mangogna A, Salviato T, Belmonte B, Cattaneo L, Monica MAT, Garzone G, Brambilla C, Pellegrinelli A, Melotti F, Testi A, Monti V, Kankava K, Gasparini P, Dagrada G, Mazzaferro V, Cotsoglou C, Collini P, Pruneri G, Milione M.

Case Rep Pathol. 2019 Nov 28;2019:4084196. doi: 10.1155/2019/4084196. eCollection 2019.

4.

The chances of hepatic resection curing hepatocellular carcinoma.

Cucchetti A, Zhong J, Berhane S, Toyoda H, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Ercolani G, Mazzaferro V, Kudo M, Cescon M, Pinna AD, Kumada T, Johnson PJ.

J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30703-2. doi: 10.1016/j.jhep.2019.11.016. [Epub ahead of print]

PMID:
31790765
5.

Comparison Between Swan-Ganz Catheter and Minimally Invasive Hemodynamic Monitoring During Liver Transplantation: Report of a Monocentric Case Series.

Villa AM, Pagano M, Fallabrino G, Piccioni F, Manzi RC, Codazzi D, Sodi F, Hila E, Germini A, Mazzaferro V, Valenza F.

Transplant Proc. 2019 Nov;51(9):2943-2947. doi: 10.1016/j.transproceed.2019.04.094. Epub 2019 Oct 10.

PMID:
31607621
6.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.

PMID:
31575541
7.

Permanent Pancreatic Duct Occlusion With Neoprene-based Glue Injection After Pancreatoduodenectomy at High Risk of Pancreatic Fistula: A Prospective Clinical Study.

Mazzaferro V, Virdis M, Sposito C, Cotsoglou C, Droz Dit Busset M, Bongini M, Flores M, Prinzi N, Coppa J.

Ann Surg. 2019 Nov;270(5):791-798. doi: 10.1097/SLA.0000000000003514.

8.

Heterologous and cross-species tropism of cancer-derived extracellular vesicles.

Garofalo M, Villa A, Crescenti D, Marzagalli M, Kuryk L, Limonta P, Mazzaferro V, Ciana P.

Theranostics. 2019 Aug 9;9(19):5681-5693. doi: 10.7150/thno.34824. eCollection 2019.

9.

Surgical Management of Hepatic Benign Disease: Have the Number of Liver Resections Increased in the Era of Minimally Invasive Approach? Analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry.

Ardito F, Aldrighetti L, Guglielmi A, Jovine E, Cillo U, Ferrero A, De Carlis L, Belli G, Dalla Valle R, Slim A, Mazzaferro V, Navarra G, Ettorre GM, Calise F, Pinna AD, Giuliante F; Italian Group of Minimally Invasive Liver Surgery (I Go MILS).

J Gastrointest Surg. 2019 Sep 10. doi: 10.1007/s11605-019-04260-7. [Epub ahead of print]

PMID:
31506894
10.

Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis.

Berardi G, Morise Z, Sposito C, Igarashi K, Panetta V, Simonelli I, Kim S, Goh BKP, Kubo S, Tanaka S, Takeda Y, Ettorre GM, Wilson GC, Cimino M, Chan CY, Torzilli G, Cheung TT, Kaneko H, Mazzaferro V, Geller DA, Han HS, Kanazawa A, Wakabayashi G, Troisi RI.

J Hepatol. 2020 Jan;72(1):75-84. doi: 10.1016/j.jhep.2019.08.032. Epub 2019 Sep 6.

PMID:
31499131
11.

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.

Prinzi N, Raimondi A, Maccauro M, Milione M, Garanzini E, Torchio M, Corti F, Nichetti F, Russo GL, Giacomelli L, Mazzaferro V, Bartolomeo MD, Seregni E, Braud F, Pusceddu S.

Future Oncol. 2019 Sep;15(26):3015-3024. doi: 10.2217/fon-2019-0138. Epub 2019 Aug 19.

PMID:
31424273
12.

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.

Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M.

Am J Transplant. 2019 Nov;19(11):3176-3184. doi: 10.1111/ajt.15551. Epub 2019 Sep 3.

PMID:
31365177
13.

Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma.

Raggi C, Fiaccadori K, Pastore M, Correnti M, Piombanti B, Forti E, Navari N, Abbadessa G, Hall T, Destro A, Di Tommaso L, Roncalli M, Meng F, Glaser S, Rovida E, Peraldo-Neia C, Olaizola P, Banales JM, Gerussi A, Elvevi A, Droz Dit Busset M, Bhoori S, Mazzaferro V, Alpini G, Marra F, Invernizzi P.

Am J Pathol. 2019 Oct;189(10):2090-2101. doi: 10.1016/j.ajpath.2019.06.007. Epub 2019 Jul 24.

PMID:
31351075
14.

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials.

Montal R, Andreu-Oller C, Bassaganyas L, Esteban-Fabró R, Moran S, Montironi C, Moeini A, Pinyol R, Peix J, Cabellos L, Villanueva A, Sia D, Mazzaferro V, Esteller M, Llovet JM.

Br J Cancer. 2019 Aug;121(4):340-343. doi: 10.1038/s41416-019-0513-7. Epub 2019 Jul 9.

PMID:
31285588
15.

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.

Ongaro E, Cremolini C, Rossini D, Corti F, Pagani F, Morelli L, Urbani L, Masi G, Sposito C, Filippi B, Borelli B, Zucchelli G, Moretto R, Boccaccino A, Solaini L, de Braud F, Mazzaferro V, Falcone A, Cucchetti A, Pietrantonio F.

ESMO Open. 2019 May 9;4(2):e000496. doi: 10.1136/esmoopen-2019-000496. eCollection 2019.

16.

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.

Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A.

J Pathol Clin Res. 2019 Oct;5(4):217-226. doi: 10.1002/cjp2.135. Epub 2019 Jul 9.

17.

The Italian Rare Pancreatic Exocrine Cancer Initiative.

Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi G, Scarpa A, Cascinu S, Silvestris N.

Tumori. 2019 Aug;105(4):353-358. doi: 10.1177/0300891619839461. Epub 2019 Apr 9.

PMID:
30967031
18.

Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.

Sposito C, Cucchetti A, Mazzaferro V.

Dig Dis Sci. 2019 Apr;64(4):1001-1007. doi: 10.1007/s10620-019-05538-1. Review.

PMID:
30852770
19.

A national mandatory-split liver policy: A report from the Italian experience.

Angelico R, Trapani S, Spada M, Colledan M, de Ville de Goyet J, Salizzoni M, De Carlis L, Andorno E, Gruttadauria S, Ettorre GM, Cescon M, Rossi G, Risaliti A, Tisone G, Tedeschi U, Vivarelli M, Agnes S, De Simone P, Lupo LG, Di Benedetto F, Santaniello W, Zamboni F, Mazzaferro V, Rossi M, Puoti F, Camagni S, Grimaldi C, Gringeri E, Rizzato L, Nanni Costa A, Cillo U.

Am J Transplant. 2019 Jul;19(7):2029-2043. doi: 10.1111/ajt.15300. Epub 2019 Mar 14.

PMID:
30748091
20.

The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future.

Sposito C, Mazzaferro V.

Hepatobiliary Surg Nutr. 2018 Dec;7(6):487-489. doi: 10.21037/hbsn.2018.10.06. No abstract available.

21.

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.

Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V.

Clin Colorectal Cancer. 2019 Mar;18(1):34-43.e6. doi: 10.1016/j.clcc.2018.11.004. Epub 2018 Nov 24.

PMID:
30558859
22.

Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice.

Garofalo M, Villa A, Rizzi N, Kuryk L, Rinner B, Cerullo V, Yliperttula M, Mazzaferro V, Ciana P.

J Control Release. 2019 Jan 28;294:165-175. doi: 10.1016/j.jconrel.2018.12.022. Epub 2018 Dec 14.

23.

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).

Vernieri C, Pusceddu S, Fucà G, Indelicato P, Centonze G, Castagnoli L, Ferrari E, Ajazi A, Pupa S, Casola S, Foiani M, Mazzaferro V, Pruneri G, Milione M, de Braud F.

Int J Cancer. 2019 Apr 1;144(7):1704-1712. doi: 10.1002/ijc.32042. Epub 2019 Jan 7.

PMID:
30520016
24.

Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt.

Virdis M, Monteleone M, Sposito C, Cascella T, Pellegrinelli A, Mazzaferro V.

J Vasc Interv Radiol. 2018 Dec;29(12):1775-1778. doi: 10.1016/j.jvir.2018.07.014. No abstract available.

PMID:
30502882
25.

Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey.

Cantù P, Tarantino I, Baldan A, Mutignani M, Tringali A, Lombardi G, Cerofolini A, Di Sario A, Catalano G, Bertani H, Ghinolfi D, Boarino V, Masci E, Bulajic M, Pisani A, Fantin A, Ligresti D, Barresi L, Traina M, Ravelli P, Forti E, Barbaro F, Costamagna G, Rodella L, Maroni L, Salizzoni M, Conigliaro R, Filipponi F, Merighi A, Staiano T, Monteleone M, Mazzaferro V, Zucchi E, Zilli M, Nadal E, Rosa R, Santi G, Parzanese I, De Carlis L, Donato MF, Lampertico P, Maggi U, Caccamo L, Rossi G, Vecchi M, Penagini R.

Liver Int. 2019 Jul;39(7):1355-1362. doi: 10.1111/liv.14010. Epub 2019 May 22.

PMID:
30500104
26.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL.

Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.

27.

Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.

Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G.

HPB (Oxford). 2019 Jun;21(6):731-738. doi: 10.1016/j.hpb.2018.10.005. Epub 2018 Nov 1.

PMID:
30391218
28.

Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.

Milione M, Maisonneuve P, Pellegrinelli A, Spaggiari P, Centonze G, Coppa J, Delconte G, Droz Dit Busset M, Lanhazo O, Pruneri G, Mazzaferro V.

Eur J Surg Oncol. 2019 May;45(5):755-760. doi: 10.1016/j.ejso.2018.10.052. Epub 2018 Oct 11.

PMID:
30366875
29.

Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies.

Garofalo M, Villa A, Rizzi N, Kuryk L, Mazzaferro V, Ciana P.

Viruses. 2018 Oct 13;10(10). pii: E558. doi: 10.3390/v10100558.

30.

Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.

Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, Kudo M, Kumada T, Roayaie S, Johnson PJ.

J Hepatol. 2018 Dec;69(6):1284-1293. doi: 10.1016/j.jhep.2018.08.027. Epub 2018 Sep 18.

31.

Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry.

Levi Sandri GB, Ettorre GM, Aldrighetti L, Cillo U, Dalla Valle R, Guglielmi A, Mazzaferro V, Ferrero A, Di Benedetto F, Gruttadauria S, De Carlis L, Vennarecci G; I Go MILS Group on HCC.

Surg Endosc. 2019 May;33(5):1451-1458. doi: 10.1007/s00464-018-6426-3. Epub 2018 Sep 10.

PMID:
30203200
32.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM.

Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14.

33.

Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?

Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, Virzì S, Mazzaferro V, Deraco M.

Dis Colon Rectum. 2018 Sep;61(9):1026-1034. doi: 10.1097/DCR.0000000000001156.

PMID:
30086051
34.

Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma.

Pinna AD, Yang T, Mazzaferro V, De Carlis L, Zhou J, Roayaie S, Shen F, Sposito C, Cescon M, Di Sandro S, Yi-Feng H, Johnson P, Cucchetti A.

Ann Surg. 2018 Nov;268(5):868-875. doi: 10.1097/SLA.0000000000002889. Erratum in: Ann Surg. 2019 Apr;269(4):e59.

PMID:
30080736
35.

Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.

Rognoni C, Ciani O, Sommariva S, Bargellini I, Bhoori S, Cioni R, Facciorusso A, Golfieri R, Gramenzi A, Mazzaferro V, Mosconi C, Ponziani F, Sacco R, Trevisani F, Tarricone R.

BMC Cancer. 2018 Jul 5;18(1):715. doi: 10.1186/s12885-018-4636-7.

36.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.

37.

A Longitudinal Investigation of Posttraumatic Growth and Quality of Life in Liver Transplant Recipients.

Gangeri L, Scrignaro M, Bianchi E, Borreani C, Bhoorie S, Mazzaferro V.

Prog Transplant. 2018 Sep;28(3):236-243. doi: 10.1177/1526924818781569. Epub 2018 Jun 26.

PMID:
29945480
38.

pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma.

Kuchuk O, Tuccitto A, Citterio D, Huber V, Camisaschi C, Milione M, Vergani B, Villa A, Alison MR, Carradori S, Supuran CT, Rivoltini L, Castelli C, Mazzaferro V.

Oncoimmunology. 2018 Mar 26;7(7):e1445452. doi: 10.1080/2162402X.2018.1445452. eCollection 2018.

39.

Reply.

Sposito C, Cucchetti A, Mazzaferro V.

Gastroenterology. 2018 Jun;154(8):2276-2277. doi: 10.1053/j.gastro.2018.05.014. Epub 2018 May 8. No abstract available.

PMID:
29750911
40.

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F.

Tumori. 2019 Apr;105(2):113-120. doi: 10.1177/0300891618765362. Epub 2018 Apr 6. Review.

PMID:
29714658
41.

Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion".

Sposito C, Spreafico C, Mazzaferro V.

J Hepatol. 2018 Jul;69(1):260-261. doi: 10.1016/j.jhep.2018.04.008. Epub 2018 Apr 27. No abstract available.

PMID:
29705239
42.

Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.

Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, Reddel S, Calvani R, Camisaschi C, Picca A, Tuccitto A, Gasbarrini A, Pompili M, Mazzaferro V.

Hepatology. 2019 Jan;69(1):107-120. doi: 10.1002/hep.30036. Epub 2018 Jul 10.

PMID:
29665135
43.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F.

Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

PMID:
29655834
44.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
45.

Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry.

Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA, Cherqui D, Filipponi F, Boudjema K, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Rasmussen A; European Liver and Intestine Transplant Association (ELITA).

HPB (Oxford). 2018 Aug;20(8):768-775. doi: 10.1016/j.hpb.2018.03.002. Epub 2018 Apr 3.

46.

Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients.

Di Sandro S, Sposito C, Lauterio A, Najjar M, Droz Dit Busset M, Buscemi V, Flores Reyes M, De Carlis R, Mazzaferro V, De Carlis L.

J Am Coll Surg. 2018 Jun;226(6):1147-1159. doi: 10.1016/j.jamcollsurg.2018.03.025. Epub 2018 Mar 21.

PMID:
29574178
47.

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPscore Working Group.

Endocr Relat Cancer. 2018 Jun;25(6):607-618. doi: 10.1530/ERC-17-0489. Epub 2018 Mar 20.

48.

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F.

Br J Cancer. 2018 Apr;118(7):955-965. doi: 10.1038/s41416-018-0015-z. Epub 2018 Mar 13.

49.

Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better.

Mazzaferro V, Droz Dit Busset M, Bhoori S.

Hepatology. 2018 Aug;68(2):775-777. doi: 10.1002/hep.29835. Epub 2018 May 14. No abstract available.

PMID:
29425402
50.

Relative Survival Instead of Overall Survival Should Be Used as Outcome When Analyzing the Effect of Age After Treatment of Hepatocellular Carcinoma.

Cucchetti A, Sposito C, Pinna AD, Mazzaferro V.

Ann Surg. 2018 Dec;268(6):e76. doi: 10.1097/SLA.0000000000002703. No abstract available.

PMID:
29420316

Supplemental Content

Loading ...
Support Center